博茨瓦纳弗朗西斯敦接受多替拉韦方案抗逆转录病毒治疗且可检测到病毒载量的HIV感染者中逆转录酶抑制剂相关耐药突变高流行
该研究利用博茨瓦纳弗朗西斯敦2023年11月至2024年1月间100份病毒载量可检测的残余HIV-1样本,评估多替拉韦方案治疗者的耐药突变。58份成功测序样本中32.8%存在任一药物类耐药突变,低水平病毒血症组与病毒学失败组相似。
要点
- 100例参与者中83.0%使用多替拉韦方案,30%为低水平病毒血症,70%为病毒学失败。
- 58份成功测序样本中32.8%(95%CI 21.8-46.0)存在任一药物类耐药突变。
- 多替拉韦方案者耐药突变总体34.8%,低水平病毒血症与病毒学失败组相似。
核心结论
- 在接受多替拉韦方案且病毒载量可检测的个体中,低水平病毒血症与病毒学失败者任一药物类耐药突变流行率均高但相似。
- 监测病毒载量可检测个体的耐药突变对保留多替拉韦方案至关重要。
研究设计与样本
- 研究利用博茨瓦纳弗朗西斯敦2023年11月至2024年1月国家抗逆转录病毒治疗项目中100份独特的HIV-1病毒载量残余样本,来自启动治疗至少6个月后仍存在病毒血症的HIV感染者。
- 病毒血症分为低水平病毒血症(病毒载量200-999拷贝/mL)和病毒学失败(病毒载量≥1000拷贝/mL)。
- 使用自建牛津纳米孔技术下一代测序对HIV-1蛋白酶、逆转录酶和整合酶基因进行测序,并通过斯坦福HIV耐药数据库的HIVdb程序鉴定耐药突变。
主要发现
- 100例参与者中83.0%使用多替拉韦方案,10.0%使用非多替拉韦方案,7.0%抗逆转录病毒方案未知或未记录。
- 30例(30%)为低水平病毒血症,70例(70%)为病毒学失败。
- 58份成功测序样本中,32.8%(95%CI 21.8-46.0)存在任一药物类耐药突变,低水平病毒血症组为33.3%(4/12),病毒学失败组为32.6%(15/46)。
- 多替拉韦方案者总体HIV耐药突变为34.8%(95%CI 22.7-49.2),低水平病毒血症组为40.0%(95%CI 16.8-68.7),病毒学失败组为33.3%(95%CI 20.2-50.0)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We assessed HIV-1 drug resistance profiles among people living with HIV (PLWH) with detectable viral load (VL) and on dolutegravir-based antiretroviral therapy (ART) in Botswana. METHODS: The study utilised available 100 residual HIV-1 VL samples from unique PLWH in Francistown who had viraemia at-least 6 months after initiating ART in Botswana's national ART program from November 2023 to January 2024. Viraemia was categorized as low-level viraemia (LLV) (VL: 200-999 copies/mL) or virologic failure (VF) (VL ≥1000 copies/mL). HIV-1 protease, reverse transcriptase and integrase genes were sequenced using an in-house next-generation sequencing Oxford nanopore technology. HIV-1 drug resistance mutations (DRMs) were identified using the HIVdb Program in the Stanford HIV drug resistance database and compared between VL groups. RESULTS: Among 100 participants, 83.0% were on dolutegravir-based, 10.0% were on non-dolutegravir-based ART and 7.0% had unknown/undocumented ART regimens. Thirty (30%) participants had LLV and 70 (70%) had VF. Among 58 successfully sequenced, 32.8% [95% Confidence Interval (CI): 21.8-46.0] had DRMs to any drug class, 33.3% (4/12) in the LLV group and 32.6% (15/46) in the VF group. Among individuals on dolutegravir-based ART, the overall HIV DRMs were 34.8% (95% CI: 22.7-49.2). By VL groups, 40.0% (95% CI: 16.8-68.7) and 33.3% (95% CI: 20.2-50.0) had DRMs at LLV and VF, respectively. CONCLUSIONS: A high but similar prevalence of any DRMs was observed among individuals with LLV and those with VF on dolutegravir-based therapy. Monitoring DRMs in individuals with detectable VL is crucial for preserving dolutegravir-based ART.
引用
- Choga OT, Lemogang GM, Choga WT, et al. High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana. J Antimicrob Chemother. 2025. PMID: 39764689. doi:10.1093/jac/dkae472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。